Table 2.
Experience at baseline of interventions in the therapeutic pathway for people with type 1 diabetes and problematic hypoglycaemia (education and technology) and stratification of randomisation in the HARPdoc RCT. N = numbers of participants with data.
| HARPdoc | BGAT | |
|---|---|---|
| Current use of diabetes technology | ||
| Insulin Pump—n (%) | [N = 47] 23 (48.9) | [N = 50] 22 (44.0) |
| Pump with automated suspend feature—n (%) | [N = 46] 8 (17.4) | [N = 50] 7 (14.0) |
| Continuous glucose monitoring (CGM)a— n (%) | [N = 47] 17 (36.2) | [N = 49] 17 (34.7) |
| Psychiatric or psychological therapies—n (%) | [N = 47] 4 (8.5) | [N = 50] 3 (6.0) |
| Retrospectively intermittently (Flash) glucose monitoring—n (%) | [N = 47] 3 (6.4) | [N = 50] 9 (18.0) |
| Currently using Bolus Advisor—n (%) | [N = 47] 27 (57.4) | [N = 50] 16 (32.0) |
| Previous education in flexible insulin therapy | ||
| Course attended—n (%) | [N = 46] | [N = 49] |
| DAFNEb | 28 (57.1) | 27 (54.0) |
| BERTIEc | 6 (12.2) | 10 (20.0) |
| DO ITd | 4 (8.2) | 4 (8.0) |
| Other structured education course | 4 (8.2) | 1 (2.0) |
| Other education | 4 (8.2) | 7 (14.0) |
| Unknown | 3 (6.1) | 1 (2.0) |
| Stratification factors by arm | ||
| Technology user vs MDI and HBGMe—n (%) | ||
| Technology | 28 (57.1) | 27 (54.0) |
| MDI and HBGM | 21 (42.9) | 23 (46.0) |
| Country of site—n (%) | ||
| UK | 41 (83.7) | 41 (82.0) |
| USA | 8 (16.3) | 9 (18.0) |
MDI multiple daily insulin injection regimen, HBGM home blood glucose monitoring (by fingerprick).
aAny real-time CGM device plus intermittently-monitored retrospective CGM (Flash) with additional on-line software providing real-time data and alarms.
bDose Adjustment for Normal Eating52.
cBournemouth Type 1 diabetes Education programme (https://www.uhd.nhs.uk/services/bdec/diabetes/structured-patient-education/bournemouth-type-1-diabetes-education-programme-bertie).
dDiabetes Outpatient Intensive Treatment Program (https://www.joslin.org/patient-care/education-programs-and-classes/do-it-program).
eTechnology = insulin pump therapy and/or continuous glucose monitoring.